Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
RISCHIN, Danny, BIBBY, David C, CHONG, Geoff, KREMMIDIOTIS, Gabriel, LESKE, Annabell F, MATTHEWS, ClaytonA, WONG, ShirleyS, ROSEN, Mark A, DESAI, Jayesh
Published in Clinical cancer research (01.08.2011)
Published in Clinical cancer research (01.08.2011)
Get full text
Journal Article
Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease
Hou, Xiaoying, Mrug, Michal, Yoder, Bradley K, Lefkowitz, Elliot J, Kremmidiotis, Gabriel, D'Eustachio, Peter, Beier, David R, Guay-Woodford, Lisa M
Published in The Journal of clinical investigation (01.02.2002)
Published in The Journal of clinical investigation (01.02.2002)
Get full text
Journal Article
The de novo chromosome 16 translocations of two patients with abnormal phenotypes (mental retardation and epilepsy) disrupt the A2BP1 gene
Bhalla, Kavita, Phillips, Hilary A, Crawford, Joanna, McKenzie, Olivia L D, Mulley, John C, Eyre, Helen, Gardner, Alison E, Kremmidiotis, Gabriel, Callen, David F
Published in Journal of human genetics (01.06.2004)
Published in Journal of human genetics (01.06.2004)
Get full text
Journal Article
ZNF652, A Novel Zinc Finger Protein, Interacts with the Putative Breast Tumor Suppressor CBFA2T3 to Repress Transcription
Kumar, Raman, Manning, Jantina, Spendlove, Hayley E, Kremmidiotis, Gabriel, McKirdy, Ross, Lee, Jaclyn, Millband, David N, Cheney, Kelly M, Stampfer, Martha R, Dwivedi, Prem P, Morris, Howard A, Callen, David F
Published in Molecular cancer research (01.09.2006)
Published in Molecular cancer research (01.09.2006)
Get full text
Journal Article
A Vascular Cell-Restricted RhoGAP, p73RhoGAP, Is a Key Regulator of Angiogenesis
Su, Zhi-Jian, Hahn, Christopher N., Goodall, Gregory J., Reck, Niamh M., Leske, Annabell F., Davy, Ann, Kremmidiotis, Gabriel, Vadas, Mathew A., Gamble, Jennifer R., Jacques F. A. P. Miller
Published in Proceedings of the National Academy of Sciences - PNAS (17.08.2004)
Published in Proceedings of the National Academy of Sciences - PNAS (17.08.2004)
Get full text
Journal Article
Localization of Human Cadherin Genes to Chromosome Regions Exhibiting Cancer-Related Loss of Heterozygosity
Kremmidiotis, Gabriel, Baker, Elizabeth, Crawford, Joanna, Eyre, Helen J., Nahmias, Joseph, Callen, David F.
Published in Genomics (San Diego, Calif.) (01.05.1998)
Published in Genomics (San Diego, Calif.) (01.05.1998)
Get full text
Journal Article
Aberrant CBFA2T3B gene promoter methylation in breast tumors
Bais, Anthony J, Gardner, Alison E, McKenzie, Olivia L D, Callen, David F, Sutherland, Grant R, Kremmidiotis, Gabriel
Published in Molecular cancer (10.08.2004)
Published in Molecular cancer (10.08.2004)
Get full text
Journal Article
Abstract 1551: Identification of plasma biomarker concentration changes resulting from the administration of the Vascular Disrupting Agent BNC105 across 3 clinical trials in mesothelioma, ovarian and renal cancer
Kremmidiotis, Gabriel, Leske, Annabel, Simpson, Jeremy, Doolin, Elizabeth, Iglesias, Jose
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Get full text
Journal Article
Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties
Flynn, Bernard L, Gill, Gurmit S, Grobelny, Damian W, Chaplin, Jason H, Paul, Dharam, Leske, Annabell F, Lavranos, Tina C, Chalmers, David K, Charman, Susan A, Kostewicz, Edmund, Shackleford, David M, Morizzi, Julia, Hamel, Ernest, Jung, M. Katherine, Kremmidiotis, Gabriel
Published in Journal of medicinal chemistry (08.09.2011)
Published in Journal of medicinal chemistry (08.09.2011)
Get full text
Journal Article
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Pal, Sumanta, Azad, Arun, Bhatia, Shailender, Drabkin, Harry, Costello, Brian, Sarantopoulos, John, Kanesvaran, Ravindran, Lauer, Richard, Starodub, Alexander, Hauke, Ralph, Sweeney, Christopher J, Hahn, Noah M, Sonpavde, Guru, Richey, Stephen, Breen, Timothy, Kremmidiotis, Gabriel, Leske, Annabell, Doolin, Elizabeth, Bibby, David C, Simpson, Jeremy, Iglesias, Jose, Hutson, Thomas
Published in Clinical cancer research (01.08.2015)
Published in Clinical cancer research (01.08.2015)
Get full text
Journal Article
Abstract B92: The tubulin-targeting agent BNC105 potentiates the efficacy of immune checkpoint inhibitors in preclinical models of colorectal cancer
Lavranos, Tina C., Beaumont, Donna, Inglis, Daniel, Scherer, Michaela, Hawkins, Chloe, Leske, Annabell F., Kremmidiotis, Gabriel
Published in Molecular cancer therapeutics (01.12.2015)
Published in Molecular cancer therapeutics (01.12.2015)
Get full text
Journal Article
BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy
Kremmidiotis, Gabriel, Leske, Annabell F, Lavranos, Tina C, Beaumont, Donna, Gasic, Jelena, Hall, Allison, O'Callaghan, Michael, Matthews, Clayton A, Flynn, Bernard
Published in Molecular cancer therapeutics (01.06.2010)
Published in Molecular cancer therapeutics (01.06.2010)
Get full text
Journal Article
Abstract 4115: BNC420 is a novel VEGFR3 selective inhibitor, which unlike the pan-VEGFR inhibitor Sunitinib, suppresses lymphatic metastasis in a model of metastatic melanoma
Leske, Annabell, Lavranos, Tina, Beaumont, Donna, Brown, Chloe, Paul, Darham, Inglis, Daniel, Scherer, Michaela, Harvey, Andrew, Kremmidiotis, Gabriel
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Get full text
Journal Article
A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma
Nowak, Anna K, Brown, Chris, Millward, Michael J, Creaney, Jenette, Byrne, Michael J, Hughes, Brett, Kremmidiotis, Gabriel, Bibby, David C, Leske, Annabell F, Mitchell, Paul L.R, Pavlakis, Nick, Boyer, Michael, Stockler, Martin R
Published in Lung cancer (Amsterdam, Netherlands) (01.09.2013)
Published in Lung cancer (Amsterdam, Netherlands) (01.09.2013)
Get full text
Journal Article
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)
Lindemann, Kristina, Beale, Philip J., Rossi, Emma, Goh, Jeff C., Vaughan, Michelle M., Tenney, Meaghan E., Martyn, Julie K., Sommeijer, Dirkje, Iglesias, Jose L., Kremmidiotis, Gabriel, Simpson, Jeremy, Doolin, Elizabeth, Lavranos, Tina C., Leske, Annabell, Veillard, Anneso S., Espinoza, David, Stockler, Martin R., Rischin, Danny
Published in Cancer chemotherapy and pharmacology (01.01.2019)
Published in Cancer chemotherapy and pharmacology (01.01.2019)
Get full text
Journal Article
Abstract B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors
Lavranos, Tina C., Inglis, Daniel, Beaumont, Donna, Leske, Annabell F., Hawkins, Chloe, Scherer, Michaela, Hart, Charles, Sun, Jessica, Elenbaas, Brian, Kremmidiotis, Gabriel
Published in Molecular cancer therapeutics (01.12.2015)
Published in Molecular cancer therapeutics (01.12.2015)
Get full text
Journal Article
The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer
Inglis, Daniel J, Lavranos, Tina C, Beaumont, Donna M, Leske, Annabell F, Brown, Chloe K, Hall, Allison J, Kremmidiotis, Gabriel
Published in Cancer biology & therapy (01.01.2014)
Published in Cancer biology & therapy (01.01.2014)
Get full text
Journal Article
Abstract B67: Induction of tumor hypoxia synergises with inhibitors of tumor metabolic and angiogenic adaptive responses to suppress tumor growth and enhance host survival
Inglis, Daniel J., Lavranos, Tina C., Beaumont, Donna M., Leske, Annabell F., Brown, Chloe K., Kremmidiotis, Gabriel
Published in Molecular cancer therapeutics (01.11.2013)
Published in Molecular cancer therapeutics (01.11.2013)
Get full text
Journal Article
Abstract 4039: Harnessing the tumor adaptive response to hypoxia to identify novel combinations of the vascular disrupting agent BNC105 with targeted therapeutics
Lavranos, Tina C., Inglis, Daniel J., Beaumont, Donna M., Leske, Annabell F., Brown, Chloe K., Kremmidiotis, Gabriel
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Get full text
Journal Article